Literature DB >> 26940764

Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis.

Donatienne Van Weehaeghe1, Jenny Ceccarini1, Aline Delva2, Wim Robberecht3, Philip Van Damme4, Koen Van Laere.   

Abstract

UNLABELLED: An objective biomarker for early identification and accurate differential diagnosis of amyotrophic lateral sclerosis (ALS) is lacking. (18)F-FDG PET brain imaging with advanced statistical analysis may provide a tool to facilitate this. The objective of this work was to validate volume-of-interest (VOI) and voxel-based (using a support vector machine [SVM] approach) (18)F-FDG PET analysis methods to differentiate ALS from controls in an independent prospective large cohort, using a priori-derived classifiers. Furthermore, the prognostic value of (18)F-FDG PET was evaluated.
METHODS: A prospective cohort of patients with a suspected diagnosis of a motor neuron disorder (n = 119; mean age ± SD, 61 ± 12 y; 81 men and 38 women) was recruited. One hundred five patients were diagnosed with ALS (mean age ± SD, 61.0 ± 12 y; 74 men and 31 women) (group 2), 10 patients with primary lateral sclerosis (mean age ± SD, 55.5 ± 12 y; 3 men and 7 women), and 4 patients with progressive muscular atrophy (mean age ± SD, 59.2 ± 5 y; 4 men). The mean disease duration of all patients was 15.0 ± 13.4 mo at diagnosis, with PET conducted 15.2 ± 13.3 mo after the first symptoms. Data were compared with a previously gathered dataset of 20 screened healthy subjects (mean age ± SD, 62.4 ± 6.4 y; 12 men and 8 women) and 70 ALS patients (mean age ± SD, 62.2 ± 12.5 y; 44 men and 26 women) (group 1). Data were spatially normalized and analyzed on a VOI basis (statistical software (using the Hammers atlas) and voxel basis using statistical parametric mapping. Discriminant analysis and SVM were used to classify new cases based on the classifiers derived from group 1.
RESULTS: Compared with controls, ALS patients showed a nearly identical pattern of hypo- and hypermetabolism in groups 1 and 2. VOI-based discriminant analysis resulted in an 88.8% accuracy in predicting the new ALS cases. For the SVM approach, this accuracy was 100%. Brain metabolism between ALS and primary lateral sclerosis patients was nearly identical and not separable on an individual basis. Extensive frontotemporal hypometabolism was predictive for a lower survival using a Kaplan-Meier survival analysis (P < 0.001).
CONCLUSION: On the basis of a previously acquired training set, (18)F-FDG PET with advanced discriminant analysis methods is able to accurately distinguish ALS from controls and aids in assessing individual prognosis. Further validation on multicenter datasets and ALS-mimicking disorders is needed to fully assess the general applicability of this approach.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  ALS; PET; discriminant analysis; prognosis; support vector machine

Mesh:

Substances:

Year:  2016        PMID: 26940764     DOI: 10.2967/jnumed.115.166272

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

Review 2.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

3.  Artificial intelligence and radiomics in nuclear medicine: potentials and challenges.

Authors:  Cumali Aktolun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12       Impact factor: 9.236

4.  Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.

Authors:  Donatienne Van Weehaeghe; Martijn Devrome; Michel Koole; Koen Van Laere; Georg Schramm; Joke De Vocht; Wies Deckers; Kristof Baete; Philip Van Damme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-20       Impact factor: 9.236

Review 5.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Authors:  Federica Agosta; Daniele Altomare; Cristina Festari; Stefania Orini; Federica Gandolfo; Marina Boccardi; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Flavio Nobili; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-01       Impact factor: 9.236

6.  Response to Deep Brain Stimulation in Three Brain Targets with Implications in Mental Disorders: A PET Study in Rats.

Authors:  Marta Casquero-Veiga; Ravit Hadar; Javier Pascau; Christine Winter; Manuel Desco; María Luisa Soto-Montenegro
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

7.  Cerebral 18F-FDG PET in macrophagic myofasciitis: An individual SVM-based approach.

Authors:  Paul Blanc-Durand; Axel Van Der Gucht; Eric Guedj; Mukedaisi Abulizi; Mehdi Aoun-Sebaiti; Lionel Lerman; Antoine Verger; François-Jérôme Authier; Emmanuel Itti
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

8.  Voxel-based mapping of grey matter volume and glucose metabolism profiles in amyotrophic lateral sclerosis.

Authors:  M-S Buhour; F Doidy; A Mondou; A Pélerin; L Carluer; F Eustache; F Viader; B Desgranges
Journal:  EJNMMI Res       Date:  2017-03-06       Impact factor: 3.138

9.  Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?

Authors:  Aline Delva; Nimish Thakore; Erik P Pioro; Koen Poesen; Rachel Saunders-Pullman; Inge A Meijer; Janet C Rucker; John T Kissel; Philip Van Damme
Journal:  Muscle Nerve       Date:  2017-05-15       Impact factor: 3.217

10.  The clinical and radiological profile of primary lateral sclerosis: a population-based study.

Authors:  Eoin Finegan; Rangariroyashe H Chipika; Stacey Li Hi Shing; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Colette Donaghy; Russell L McLaughlin; Niall Pender; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2019-07-19       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.